Opiant Pharmaceuticals, Inc. (OPNT) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
233 WILSHIRE BLVD SANTA MONICA, CA 90401 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2022 MRQ | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 7/31/2017 | 7/31/2016 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 52,869 | 48,251 | 30,980 | 24,614 | 6,873 | 1,481 | |||
| Cash and cash equivalents | 37,854 | 48,251 | 30,980 | 24,614 | 6,873 | 1,481 | |||
| Short-term investments | 15,015 | ||||||||
| Receivables | 13,327 | 8,911 | 7,218 | 4,489 | 3,750 | 312 | |||
| Prepaid expense | 62 | ||||||||
| Other undisclosed current assets | 2,963 | 1,937 | 1,056 | 268 | 165 | ||||
| Total current assets: | 69,159 | 59,099 | 39,255 | 29,371 | 10,787 | 1,856 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 1,000 | 278 | 768 | ✕ | ✕ | ✕ | |||
| Property, plant and equipment | 78 | 171 | 243 | 3 | 7 | ||||
| Intangible assets, net (including goodwill) | 12 | 13 | 14 | 16 | 18 | 19 | |||
| Intangible assets, net (excluding goodwill) | 12 | 13 | 14 | 16 | 18 | 19 | |||
| Other noncurrent assets | 180 | 1,051 | |||||||
| Total noncurrent assets: | 1,269 | 1,514 | 1,026 | 16 | 20 | 26 | |||
| TOTAL ASSETS: | 70,428 | 60,613 | 40,281 | 29,386 | 10,808 | 1,882 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 3,370 | 2,966 | 1,317 | 1,133 | 2,212 | 141 | |||
| Employee-related liabilities | ✕ | 201 | 909 | 1,238 | 1,084 | 1,701 | 3,681 | ||
| Accrued liabilities | 2,920 | 1,908 | 1,620 | 998 | 929 | ||||
| Other undisclosed accounts payable and accrued liabilities | 248 | 150 | (1,541) | (949) | (418) | (3,541) | |||
| Deferred revenue | 17 | 355 | 918 | ✕ | ✕ | ✕ | |||
| Debt | 517 | 165 | |||||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | 1,212 | 254 | 250 | ||
| Other undisclosed current liabilities | 3,459 | 3,099 | 2,858 | 7,482 | 1,701 | 3,681 | |||
| Total current liabilities: | 6,846 | 6,420 | 5,610 | 9,827 | 4,167 | 4,237 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 673 | 255 | |||||||
| Liabilities, other than long-term debt | 440 | 282 | 2,307 | 2,350 | |||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | 2,307 | 2,350 | ||
| Accounts payable and accrued liabilities | 440 | 282 | |||||||
| Operating lease, liability | 673 | 255 | ✕ | ✕ | ✕ | ||||
| Other undisclosed noncurrent liabilities | 15,629 | 18,419 | 2,700 | ||||||
| Total noncurrent liabilities: | 16,742 | 18,701 | 255 | 2,700 | 2,307 | 2,350 | |||
| Total liabilities: | 23,588 | 25,121 | 5,864 | 12,527 | 6,473 | 6,587 | |||
| Equity | |||||||||
| Equity, attributable to parent | 46,840 | 35,492 | 34,416 | 16,859 | 4,334 | (4,705) | |||
| Common stock | 5 | 4 | 4 | 4 | 2 | 2 | |||
| Additional paid in capital | 108,570 | 100,204 | 97,239 | 91,276 | 58,937 | 56,478 | |||
| Accumulated other comprehensive loss | (55) | (27) | |||||||
| Accumulated deficit | (61,680) | (64,689) | (62,828) | (74,421) | (54,605) | (61,185) | |||
| Total equity: | 46,840 | 35,492 | 34,416 | 16,859 | 4,334 | (4,705) | |||
| TOTAL LIABILITIES AND EQUITY: | 70,428 | 60,613 | 40,281 | 29,386 | 10,808 | 1,882 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2022 TTM | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 7/31/2017 | 7/31/2016 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 47,785 | 29,625 | 40,520 | 13,982 | 18,446 | 9,898 | ||
| Revenue, net | ✕ | ✕ | ✕ | ✕ | 13,262 | 18,406 | 5,098 | |
| Cost of revenue (Cost of Goods and Services Sold) | (13,725) | |||||||
| Gross profit: | 47,785 | 29,625 | 40,520 | 257 | 18,446 | 9,898 | ||
| Operating expenses | (42,629) | (31,866) | (29,608) | (35,173) | (11,353) | (17,636) | ||
| Other undisclosed operating income | 13,725 | |||||||
| Operating income (loss): | 5,156 | (2,241) | 10,911 | (21,190) | 7,093 | (7,738) | ||
| Nonoperating income (expense) | (2,123) | (46) | 504 | 46 | 38 | (76) | ||
| Gain (loss), foreign currency transaction, before tax | (6) | (9) | 50 | (48) | 18 | (64) | ||
| Interest and debt expense | (2,129) | (131) | 17 | |||||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | 131 | (17) | ||||||
| Income (loss) from continuing operations before equity method investments, income taxes: | 904 | (2,287) | 11,416 | (21,144) | 7,131 | (7,814) | ||
| Other undisclosed income from continuing operations before income taxes | 2,129 | |||||||
| Income (loss) from continuing operations before income taxes: | 3,033 | (2,287) | 11,416 | (21,144) | 7,131 | (7,814) | ||
| Income tax expense (benefit) | (24) | 426 | 177 | (51) | (550) | |||
| Income (loss) from continuing operations: | 3,009 | (1,861) | 11,593 | (21,195) | 6,581 | (7,814) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | 3,009 | (1,861) | 11,593 | (21,195) | 6,581 | (7,814) | |
| Net income (loss) available to common stockholders, diluted: | 3,009 | (1,861) | 11,593 | (21,195) | 6,581 | (7,814) | ||
Comprehensive Income ($ in thousands)
| 9/30/2022 TTM | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 7/31/2017 | 7/31/2016 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 3,009 | (1,861) | 11,593 | (21,195) | 6,581 | (7,814) | ||
| Comprehensive income (loss): | 3,009 | (1,861) | 11,593 | (21,195) | 6,581 | (7,814) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (28) | (27) | ||||||
| Comprehensive income (loss), net of tax, attributable to parent: | 2,981 | (1,888) | 11,593 | (21,195) | 6,581 | (7,814) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.